Vincerx Pharma Inc [NASDAQ: VINC] closed the trading session at $0.15.
The stocks have a year to date performance of -41.89 percent and weekly performance of -26.23 percent. The stock has been moved at -77.55 percent over the last six months. The stock has performed -17.46 percent around the most recent 30 days and changed -62.30 percent over the most recent 3-months.
If compared to the average trading volume of 7.02M shares, VINC reached to a volume of 3496377 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Vincerx Pharma Inc [VINC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VINC shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VINC stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Vincerx Pharma Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 14, 2022. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on December 23, 2021, representing the official price target for Vincerx Pharma Inc stock. Previously, the target price had yet another raise to $24, while SVB Leerink analysts kept a Outperform rating on VINC stock.
The Average True Range (ATR) for Vincerx Pharma Inc is set at 0.04 The Price to Book ratio for the last quarter was 0.53, with the Price to Cash per share for the same quarter was set at 0.28.
VINC stock trade performance evaluation
Vincerx Pharma Inc [VINC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -26.23. With this latest performance, VINC shares dropped by -17.46% in over the last four-week period, additionally sinking by -77.55% over the last 6 months – not to mention a drop of -88.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VINC stock in for the last two-week period is set at 35.55, with the RSI for the last a single of trading hit 31.95, and the three-weeks RSI is set at 36.40 for Vincerx Pharma Inc [VINC]. The present Moving Average for the last 50 days of trading for this stock 0.2481, while it was recorded at 0.1771 for the last single week of trading, and 0.7287 for the last 200 days.
Vincerx Pharma Inc [VINC]: An insightful look at the core fundamentals
Vincerx Pharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.17 and a Current Ratio set at 2.17.
Vincerx Pharma Inc [VINC]: Institutional Ownership
There are presently around $24.40%, or 28.98%% of VINC stock, in the hands of institutional investors. The top three institutional holders of VINC stocks are: PROSIGHT MANAGEMENT, LP with ownership of 2.49 million shares, which is approximately 11.6281%. ARMISTICE CAPITAL, LLC, holding 1.99 million shares of the stock with an approximate value of $$1.61 million in VINC stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$1.38 million in VINC stock with ownership which is approximately 7.9599%.
